Document is current
Any future updates will be listed below
-
Authors
Blasiak, Agata
Truong, Anh T. L. https://orcid.org/0000-0003-1551-4437
Foo, Nigel
Tan, Lester W. J. https://orcid.org/0000-0003-0323-4964
Kumar, Kirthika S.
Tan, Shi-Bei https://orcid.org/0000-0001-6388-4390
Teo, Chong Boon
Tan, Benjamin K. J.
Tadeo, Xavier https://orcid.org/0000-0003-0356-826X
Tan, Hon Lyn
Chee, Cheng Ean
Yong, Wei Peng
Ho, Dean https://orcid.org/0000-0002-7337-296X
Sundar, Raghav https://orcid.org/0000-0001-9423-1368
-
Funding
Funding for this research was provided by:
MOH | National Medical Research Council (NMRC/TA/0014/2020, MOH-OFLCG18May-0003, NMRC/CG/M005/2017)
National Research Foundation Singapore (AISG-GC-2019-002, A20G8b0102)
Ministry of Health -Singapore (MOH-OFLCG18May-0028)
National University of Singapore (R-719-000-037-733)
Ministry of Education - Singapore (R-397-000-333-114)
- License Information
-
More Information
Article History
Received: 24 April 2024
Accepted: 6 February 2025
First Online: 21 February 2025
Competing interests
: D.H. reports equity in KYAN Therapeutics. RS reports support from Bristol Myers Squibb, Merck, Eisai, Bayer, Taiho, Novartis, Eli Lilly, Roche, AstraZeneca, DKSH, MSD, Paxman Coolers, Natera, Astellas, GSK, Ipsen, Tavotek, Pierre-Fabre, Beigene, CytoMed, GSK, Daiichi-Sankyo outside the submitted work. C.E.C. reports consulting/advisory roles for GuardantHealth AMEA, Roche Genentech, AstraZeneca, Merck, and honoraria from AstraZeneca, Roche Genentech, PierreFabre, Merck, Amgen. WPY reports support from Abbvie/Genentech, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, MSD Oncology, Novartis, and Taiho Pharmaceutical. A.B., A.T.L.T., L.W.J.T., K.S.K., S.-B.T., and D.H. are coinventors of previously filed pending patent(s) on artificial intelligence-based therapy development. The other authors declare no competing interests.
